Orchestra BioMed CEO to Present at H.C. Wainwright Conference Amid Pivotal Trials
Event summary
- Orchestra BioMed CEO David Hochman will present at H.C. Wainwright's 28th Annual Global Investment Conference on September 16, 2026.
- The company is advancing two flagship products: AVIM Therapy for hypertension and Virtue SAB for atherosclerotic artery disease.
- AVIM Therapy has FDA Breakthrough Device Designation and a strategic collaboration with Medtronic.
- Virtue SAB also has FDA Breakthrough Device Designation for multiple indications.
The big picture
Orchestra BioMed's participation in the H.C. Wainwright conference comes as it navigates pivotal clinical trials for two high-impact products targeting multi-billion-dollar markets. The strategic collaboration with Medtronic for AVIM Therapy underscores the company's focus on accelerating bioelectronic treatments for hypertension, while Virtue SAB aims to disrupt drug delivery in atherosclerotic artery disease. The FDA's Breakthrough Device Designations for both products highlight their potential to address significant unmet medical needs.
What we're watching
- Clinical Progress
- The pace at which AVIM Therapy and Virtue SAB advance through pivotal clinical trials will determine their market potential.
- Regulatory Dynamics
- The impact of FDA Breakthrough Device Designations on expedited approval timelines for both products.
- Strategic Partnerships
- How the collaboration with Medtronic will influence the commercialization of AVIM Therapy.